VRTX Vertex Pharmaceuticals Incorpor

117.26
+3  (2%)
Previous Close 114.63
Open 115.20
Price To book 24.61
Market Cap 29.13B
Shares 248,438,000
Volume 1,495,498
Short Ratio 3.45
Av. Daily Volume 1,867,700

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - Two Copies of the F508del Mutation
Phase 2 data due 2H 2017.
VX-440 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Phase 2 data due 2H 2017
VX-152 in combination with tezacaftor and ivacaftor
Cystic fibrosis who have one F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation
Approved December 29, 2014.
KALYDECO
Cystic fibrosis (CF) ages 6 and older who have the R117H mutation
Phase 3 data released March 28, 2017 - primary endpoint met. NDA filing due 3Q 2017.
Tezacaftor (VX-661) / ivacaftor
Cystic fibrosis - One Copy of the F508del Mutation and a Second Mutation that Results in Residual CFTR Function
Phase 2 primary endpoint met - January 25, 2017.
VX-150
Osteoarthritis
CRL issued February 5, 2016.
KALYDECO (ivacaftor)
Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.
Approved July 2, 2015.
Lumacaftor and ivacaftor
Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation
Approved March 17, 2015.
KALYDECO (ivacaftor)
Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations
Phase 3 data released November 7, 2016 met primary endpoint.
ORKAMBI
Two Copies of the F508del Mutation
Enrollment is expected to complete in 1H 2017.
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation
Phase 3 trial terminated August 2016
VX-661
Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function
Approved September 28, 2016.
ORKAMBI
Cystic fibrosis (CF) ages 6-11 who have F508del mutation

Latest News

  1. Trump invites ​Vertex CEO to White House for biotech summit
  2. ​Vertex at odds with religious investors over lobbying disclosures
  3. Zacks.com featured highlights: PTC, Covanta Holding, Live Nation Entertainment, Incyte and Vertex Pharmaceuticals
  4. ​Vertex CEO's compensation, stock value fell in 2016
  5. Retirement Accounts Benefit From Columbia Fund's Tech Bets
  6. Vertex to Announce First Quarter 2017 Financial Results on April 27
  7. Protalix Cystic Fibrosis Drug Study Results Worsen Over Time
  8. 3 Best Performing Stocks in March
  9. What's Next for Corbus Pharmaceuticals After Its Controversial Cystic Fibrosis Results?
  10. The Zacks Analyst Blog Highlights: Esperion Therapeutics, Vertex Pharmaceuticals, Nektar Therapeutics, Argos Therapeutics and Cidara Therapeutics
  11. 3 Great Stocks on Sale to Buy Today
  12. 15 companies with outsized sales growth and widening profit margins
  13. 3 Top Stocks to Buy in Q2
  14. Greenbrier And Vertex Maintain Bullish Bias, Stamps.com Breaking Down
  15. Stocks To Watch In Market Weakness
  16. Harry Boxer’s four stocks to watch
  17. Vertex Pharmaceuticals (VRTX) Shares March Higher, Can It Continue?
  18. 3 of the Best & Worst Performing Drug Stocks of Q1
  19. Is Vertex Pharmaceuticals the Best Biotech Stock?
  20. Amgen Files for Xgeva Label Expansion, To Include Myeloma